Calc Function

    • Calcs that help predict probability of a diseaseDiagnosis
    • Subcategory of 'Diagnosis' designed to be very sensitiveRule Out
    • Disease is diagnosed: prognosticate to guide treatmentPrognosis
    • Numerical inputs and outputsFormula
    • Med treatment and moreTreatment
    • Suggested protocolsAlgorithm

    Disease

    Select...

    Specialty

    Select...

    Chief Complaint

    Select...

    Organ System

    Select...

    Patent Pending

    Log In

    Show
    Forgot your password?
    Log In
    Or create a new account (it's free)

    Forgot Password?

    Enter your email address and we'll send you a link to reset your password.

    Get New Password

    Sign In Required

    To save favorites, you must log in.

    Creating an account is free, easy, and takes about 60 seconds.

    Already have an MDCalc account?

    Login to link your favorites and recently used calcs

    Show
    Forgot your password?
    Log In
    Or continue to Nuance

    Attention COACH STUDY participants:

    The principal investigators of the study request that you use the official version of the modified score here.

    Manchester Score for Prognosis in Small Cell Lung Cancer

    Predicts 2 year survival of small cell lung cancer.
    When to Use
    Pearls/Pitfalls

    It has been used to determine when to administer chemotherapy in the ICU to admitted lung cancer patients.(Zarogoulidis 2013)

    The score distinguishes three prognostic groups with overall two-year survival rates of 16.2%, 2.5%, and 0%.

    No
    0
    Yes
    +1
    No
    0
    Yes
    +1
    No
    0
    Yes
    +1
    No
    0
    Yes
    +1
    No
    0
    Yes
    +1
    100 -- Normal. No complaints. No evidence of disease.
    90 -- Able to carry on normal activity. Minor signs or symptoms of disease.
    80 -- Normal activity with effort. Some signs or symptoms of disease.
    70 -- Cares for self. Unable to carry on normal activity or to do active work.
    60 -- Requires occasional assistance, but is able to care for most of his/her personal needs.
    50 -- Requires considerable assistance and frequent medical care.
    40 -- Disabled. Requires special care and assistance.
    30 -- Severely disabled. Hospital admission is indicated although death not imminent.
    20 -- Very sick. Hospital admission necessary. Active supportive treatment necessary.
    10 -- Moribund. Fatal processes progressing rapidly.

    Result:

    Please fill out required fields.

    Next Steps
    Evidence
    Creator Insights
    Dr. Thomas Cerny

    From the Creator

    What pearls, pitfalls and/or tips do you have for users of the Manchester Score for Lung Cancer? Do you know of cases when it has been applied, interpreted, or used inappropriately?

    It’s easy to use and the therapeutic options are pretty much the same as today. Only bicarbonate might not be used routinely, but it’s easy and cheap. This might change in the near future with the advent of new treatment options, but I have not heard as to any pitfalls with the Manchester Score.

    What recommendations do you have for doctors once they have applied the Manchester Score for Lung Cancer? Are there any adjustments or updates you would make to the score based on new data or practice changes?

    Not to my knowledge.

    Why did you develop the Manchester Score for Lung Cancer? Was there a particular clinical experience or patient encounter that inspired you to create this tool for clinicians?

    35 years ago, more prognostic information was asked by patients and treating physicians for, i.e., shared decision making, and since there is a small chance of cure in SCLC, any prognostically validated information could help to make the best treatment choice in individual cases.

    How do you use the Manchester Score for Lung Cancer in your own clinical practice? Can you give an example of a scenario in which you use it?

    N/A - I am retired since a few years and no more treating patients.

    About the Creator

    Thomas Cerny, MD, is the former chief of hematology and oncology at Kantonsspital St Gallen and also a professor of medical oncology at the University of Berne. He is president of the Swiss Cancer Foundation and Oncosuisse. Dr. Cerny researches multiple types of cancer including sarcoma and lung cancer.

    To view Dr. Thomas Cerny's publications, visit PubMed

    Are you Dr. Thomas Cerny? Send us a message to review your photo and bio, and find out how to submit Creator Insights!
    MDCalc loves calculator creators – researchers who, through intelligent and often complex methods, discover tools that describe scientific facts that can then be applied in practice. These are real scientific discoveries about the nature of the human body, which can be invaluable to physicians taking care of patients.
    About the Creator
    Dr. Thomas Cerny
    Are you Dr. Thomas Cerny?